| 1 | vs | 40,765 |
| 2 | plus/minus | 20 |
| 3 | ─ | 20 |
| 4 | /bpo | 16 |
| 5 | -bpo | 13 |
| 6 | -bupivacaine | 9 |
| 7 | /moxidectin | 5 |
| 8 | lidocaine-medicated | 5 |
| 9 | -box | 3 |
| 10 | mg→15 | 3 |
| 11 | -1,3-oxazin-4-one | 2 |
| 12 | -inadequate | 2 |
| 13 | -v- | 2 |
| 14 | /flumethrin | 2 |
| 15 | 0.73- | 2 |
| 16 | aquilion | 2 |
| 17 | female/ | 2 |
| 18 | pyrimidin- | 2 |
| 19 | 'christoph | 1 |
| 20 | ,13/ | 1 |
| 21 | -2-p-tolyloxy-quinoline | 1 |
| 22 | -3= | 1 |
| 23 | -b2 | 1 |
| 24 | -encompassing | 1 |
| 25 | .mothers | 1 |
| 26 | .once-daily | 1 |
| 27 | .though | 1 |
| 28 | /a-v | 1 |
| 29 | /fvc= | 1 |
| 30 | /operation | 1 |
| 31 | /sulfur | 1 |
| 32 | /very | 1 |
| 33 | 0.57± | 1 |
| 34 | 001/16 | 1 |
| 35 | 1.29- | 1 |
| 36 | 18.7±11.9 | 1 |
| 37 | 253-32 | 1 |
| 38 | 420±1 | 1 |
| 39 | 513-44 | 1 |
| 40 | 6.81± | 1 |
| 41 | 705±1 | 1 |
| 42 | 925±3 | 1 |
| 43 | aquillion | 1 |
| 44 | bupivacain,20ml | 1 |
| 45 | byori | 1 |
| 46 | cat-activity | 1 |
| 47 | celfuroxime | 1 |
| 48 | chelex-100 | 1 |
| 49 | ci=- | 1 |
| 50 | ci=1.4- | 1 |
| 51 | ci=45-1 | 1 |
| 52 | citalopram/40 | 1 |
| 53 | complete/very | 1 |
| 54 | decylrhodamine | 1 |
| 55 | dithiazine-3-carbonitriles | 1 |
| 56 | dithiazines | 1 |
| 57 | e.def | 1 |
| 58 | ersus | 1 |
| 59 | fibrinolysis-rescue | 1 |
| 60 | fibrinolysis-urgent/elective | 1 |
| 61 | flb | 1 |
| 62 | gesundheitsschutz | 1 |
| 63 | hlas | 1 |
| 64 | imidacloprid/ | 1 |
| 65 | isothiazole-3-carbonitriles | 1 |
| 66 | isothiazoles | 1 |
| 67 | isothiourea | 1 |
| 68 | isoxazol-3-yl-aryl-methanones | 1 |
| 69 | lidocaine/ | 1 |
| 70 | m/s/week | 1 |
| 71 | ml+fentanyl | 1 |
| 72 | mrs5679 | 1 |
| 73 | mr≥grade | 1 |
| 74 | na-doped | 1 |
| 75 | nswsc | 1 |
| 76 | n₂and | 1 |
| 77 | o2max= | 1 |
| 78 | pyrimidine-4-one | 1 |
| 79 | recipients/35 | 1 |
| 80 | ropivacaine+fentanyl | 1 |
| 81 | ropivacaine/1ml | 1 |
| 82 | trithiazepine-4-carbonitriles | 1 |
| 83 | tween® | 1 |
| 84 | usl255/topamax-ratio | 1 |
| 85 | ∙0.5 | 1 |
| 86 | ∙3 | 1 |
| 1 | 'christoph | 1 |
| 2 | ,13/ | 1 |
| 3 | -1,3-oxazin-4-one | 2 |
| 4 | -2-p-tolyloxy-quinoline | 1 |
| 5 | -3= | 1 |
| 6 | -b2 | 1 |
| 7 | -box | 3 |
| 8 | -bpo | 13 |
| 9 | -bupivacaine | 9 |
| 10 | -encompassing | 1 |
| 11 | -inadequate | 2 |
| 12 | -v- | 2 |
| 13 | .mothers | 1 |
| 14 | .once-daily | 1 |
| 15 | .though | 1 |
| 16 | /a-v | 1 |
| 17 | /bpo | 16 |
| 18 | /flumethrin | 2 |
| 19 | /fvc= | 1 |
| 20 | /moxidectin | 5 |
| 21 | /operation | 1 |
| 22 | /sulfur | 1 |
| 23 | /very | 1 |
| 24 | 0.57± | 1 |
| 25 | 0.73- | 2 |
| 26 | 001/16 | 1 |
| 27 | 1.29- | 1 |
| 28 | 18.7±11.9 | 1 |
| 29 | 253-32 | 1 |
| 30 | 420±1 | 1 |
| 31 | 513-44 | 1 |
| 32 | 6.81± | 1 |
| 33 | 705±1 | 1 |
| 34 | 925±3 | 1 |
| 35 | aquilion | 2 |
| 36 | aquillion | 1 |
| 37 | bupivacain,20ml | 1 |
| 38 | byori | 1 |
| 39 | cat-activity | 1 |
| 40 | celfuroxime | 1 |
| 41 | chelex-100 | 1 |
| 42 | ci=- | 1 |
| 43 | ci=1.4- | 1 |
| 44 | ci=45-1 | 1 |
| 45 | citalopram/40 | 1 |
| 46 | complete/very | 1 |
| 47 | decylrhodamine | 1 |
| 48 | dithiazine-3-carbonitriles | 1 |
| 49 | dithiazines | 1 |
| 50 | e.def | 1 |
| 51 | ersus | 1 |
| 52 | female/ | 2 |
| 53 | fibrinolysis-rescue | 1 |
| 54 | fibrinolysis-urgent/elective | 1 |
| 55 | flb | 1 |
| 56 | gesundheitsschutz | 1 |
| 57 | hlas | 1 |
| 58 | imidacloprid/ | 1 |
| 59 | isothiazole-3-carbonitriles | 1 |
| 60 | isothiazoles | 1 |
| 61 | isothiourea | 1 |
| 62 | isoxazol-3-yl-aryl-methanones | 1 |
| 63 | lidocaine-medicated | 5 |
| 64 | lidocaine/ | 1 |
| 65 | m/s/week | 1 |
| 66 | mg→15 | 3 |
| 67 | ml+fentanyl | 1 |
| 68 | mrs5679 | 1 |
| 69 | mr≥grade | 1 |
| 70 | na-doped | 1 |
| 71 | nswsc | 1 |
| 72 | n₂and | 1 |
| 73 | o2max= | 1 |
| 74 | plus/minus | 20 |
| 75 | pyrimidin- | 2 |
| 76 | pyrimidine-4-one | 1 |
| 77 | recipients/35 | 1 |
| 78 | ropivacaine+fentanyl | 1 |
| 79 | ropivacaine/1ml | 1 |
| 80 | trithiazepine-4-carbonitriles | 1 |
| 81 | tween® | 1 |
| 82 | usl255/topamax-ratio | 1 |
| 83 | vs | 40,765 |
| 84 | ∙0.5 | 1 |
| 85 | ∙3 | 1 |
| 86 | ─ | 20 |
| 1 | 0.73- | 2 |
| 2 | ci=1.4- | 1 |
| 3 | 1.29- | 1 |
| 4 | ci=- | 1 |
| 5 | pyrimidin- | 2 |
| 6 | -v- | 2 |
| 7 | ,13/ | 1 |
| 8 | imidacloprid/ | 1 |
| 9 | female/ | 2 |
| 10 | lidocaine/ | 1 |
| 11 | chelex-100 | 1 |
| 12 | citalopram/40 | 1 |
| 13 | ci=45-1 | 1 |
| 14 | 420±1 | 1 |
| 15 | 705±1 | 1 |
| 16 | 253-32 | 1 |
| 17 | -b2 | 1 |
| 18 | ∙3 | 1 |
| 19 | 925±3 | 1 |
| 20 | 513-44 | 1 |
| 21 | ∙0.5 | 1 |
| 22 | mg→15 | 3 |
| 23 | recipients/35 | 1 |
| 24 | 001/16 | 1 |
| 25 | 18.7±11.9 | 1 |
| 26 | mrs5679 | 1 |
| 27 | -3= | 1 |
| 28 | /fvc= | 1 |
| 29 | o2max= | 1 |
| 30 | isothiourea | 1 |
| 31 | flb | 1 |
| 32 | nswsc | 1 |
| 33 | na-doped | 1 |
| 34 | lidocaine-medicated | 5 |
| 35 | n₂and | 1 |
| 36 | mr≥grade | 1 |
| 37 | celfuroxime | 1 |
| 38 | -bupivacaine | 9 |
| 39 | -2-p-tolyloxy-quinoline | 1 |
| 40 | decylrhodamine | 1 |
| 41 | pyrimidine-4-one | 1 |
| 42 | -1,3-oxazin-4-one | 2 |
| 43 | -inadequate | 2 |
| 44 | fibrinolysis-rescue | 1 |
| 45 | fibrinolysis-urgent/elective | 1 |
| 46 | e.def | 1 |
| 47 | -encompassing | 1 |
| 48 | .though | 1 |
| 49 | 'christoph | 1 |
| 50 | byori | 1 |
| 51 | m/s/week | 1 |
| 52 | bupivacain,20ml | 1 |
| 53 | ropivacaine/1ml | 1 |
| 54 | ropivacaine+fentanyl | 1 |
| 55 | ml+fentanyl | 1 |
| 56 | /flumethrin | 2 |
| 57 | /moxidectin | 5 |
| 58 | aquilion | 2 |
| 59 | aquillion | 1 |
| 60 | /operation | 1 |
| 61 | usl255/topamax-ratio | 1 |
| 62 | -bpo | 13 |
| 63 | /bpo | 16 |
| 64 | /sulfur | 1 |
| 65 | hlas | 1 |
| 66 | isothiazole-3-carbonitriles | 1 |
| 67 | dithiazine-3-carbonitriles | 1 |
| 68 | trithiazepine-4-carbonitriles | 1 |
| 69 | isothiazoles | 1 |
| 70 | dithiazines | 1 |
| 71 | isoxazol-3-yl-aryl-methanones | 1 |
| 72 | .mothers | 1 |
| 73 | plus/minus | 20 |
| 74 | ersus | 1 |
| 75 | vs | 40,765 |
| 76 | /a-v | 1 |
| 77 | -box | 3 |
| 78 | .once-daily | 1 |
| 79 | /very | 1 |
| 80 | complete/very | 1 |
| 81 | cat-activity | 1 |
| 82 | gesundheitsschutz | 1 |
| 83 | ─ | 20 |
| 84 | tween® | 1 |
| 85 | 6.81± | 1 |
| 86 | 0.57± | 1 |